来适可联合非诺贝特治疗混合性高脂血症临床评价  

Clinical evaluation of Fluvstatin united Fenofibrate in treatment of mixed hyperlipidemia

作　　者：李亚云[1] 

机构地区：[1]江苏省南通市肿瘤医院南院27病区,江苏南通226006

出　　处：《中国医药导报》2011年第8期73-74,共2页China Medical Herald

摘　　要：目的:探讨来适可联合非诺贝特治疗混合性高脂血症临床效果。方法:随机选择2008年11月～2010年4月混合性高脂血症患者70例,治疗前均停用原降脂药物,并服用2周安慰剂作为洗脱期,晨口服非诺贝特100 mg,晚口服来适可10 mg,每晚1次。结果:治疗后TC、LDL-C、TG下降,HDL-C增加,治疗前后比较差异均有统计学意义(均P<0.05)。治疗效果显效50例,好转12例,无效8例,总有效率为89.33%(67/75)。治疗中有2例出现胃肠道反应,2例出现转氨酶升高,停药后恢复正常,其他肝、肾功能指标均正常,无肌痛发生。结论:联合应用来适可和贝特类的调脂作用较为合理和全面,尤其适用于TC、LDL-C和TG升高伴有HDL-C降低者,其疗效确切,安全有效,副作用小,值得临床进一步探讨和研究。Objective： To explore clinical effects of Fluvstatin united Fenofibrate in treatment of mixed hyperlipidemia. Methods： Seventy patients with mixed hyperlipidemia were randomly selected from November 2008 to April 2010, original lipid-lowering agents were discontinued before treatment, and taking 2 weeks placebo as elution period, morning oral Fenofibrate 100 mg, late oral Fluvstatin 10 mg, every night 1 time. Results： After the treatment, TC, LDL-C and TG declined, HDL-C level increased, compared before and after treatment there were significant difference （all P〈0.05）. Healing 50 cases, improvement in 12 cases, invalid in 8 cases, the total effective rate for 89.33% （67/75）. During treatment 2 patients suffered from gastrointestinal reaction, 2 cases with transaminase increasing, after discontinuation normal liver, renal function and other reactive index were all normal, no myalgia happening. Conclusion： Combined application of Fluvstatin and Fibrates adjustment function is more reasonable and comprehensive, particularly suitable for patients with TC, LDL-C and TG rising and tlDL-C reducing, with definite effect, safe and effective, side effect is small, and is worth clinical further discussion and study.

关 键 词：来适可 非诺贝特 混合性高脂血症 

分 类 号：R589.2[医药卫生—内分泌]